Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin

Elias S. Sotirchos, Eleni S. Vasileiou, Rebecca Salky, Saif Huda, Sara Mariotto, John J. Chen, Michael Levy

Research output: Contribution to journalLetterpeer-review

Abstract

Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.

Original languageEnglish (US)
Article number103462
JournalMultiple Sclerosis and Related Disorders
Volume57
DOIs
StatePublished - Jan 2022

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin'. Together they form a unique fingerprint.

Cite this